Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Is Madrigal Pharmaceuticals a Millionaire Maker?
12:02pm, Sunday, 30'th Jun 2024
Madrigal Pharmaceutical is the only biotech in its market. Its market is likely to be a fairly large one.
Is Madrigal Pharmaceuticals Stock a Buy?
06:45am, Friday, 28'th Jun 2024
Madrigal Pharmaceuticals earned an important regulatory approval this year. However, the biotech faces risks, including the need for a post-marketing study.
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
12:05pm, Sunday, 16'th Jun 2024
Madrigal Pharmaceuticals is the only company with an approved drug for MASH. Eli Lilly's latest clinical trial data shows that its candidate may perform even better.
Where Will Madrigal Pharmaceuticals Be in 3 Years?
09:45am, Saturday, 15'th Jun 2024
Madrigal Pharmaceuticals currently has undisputed dominance in its main market. There are powerful actors trying to elbow their way in and change that status.
Madrigal Pharma CEO talks competition in the GLP-1 space and new drug rollouts
07:28pm, Thursday, 13'th Jun 2024
Bill Sibold, Madrigal Pharma CEO, joins 'Fast Money' to talk GLP-1 drug competition, its liver disease treatment, its Mash drug rollout and more.
Madrigal Pharmaceuticals: The GLP-1 Threat May Be Overcooked
10:16am, Wednesday, 12'th Jun 2024
Madrigal Pharmaceuticals, Inc. stock has enjoyed peaks and troughs as it has pursued its path to the approval of NASH drug Rezdiffra. The company's stock was buoyant yesterday, enjoying a 15% gain aft
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
09:45am, Monday, 10'th Jun 2024
Madrigal Pharmaceuticals has a monopoly in its main market -- for the moment. Viking Therapeutics has a good candidate, but it could face powerful competitors.
CONSHOHOCKEN, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis
Is Madrigal Pharmaceuticals Stock a Buy?
09:45am, Tuesday, 21'st May 2024
Madrigal Pharmaceuticals recently earned an impressive approval from the FDA. The biotech still has work to do to reach its peak potential with this medicine.
Amalgamated Bank Raises Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
05:00am, Monday, 20'th May 2024
Amalgamated Bank boosted its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 2.8% during the 4th quarter, according to the company in its most recent disclosure with th
Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript
11:24am, Tuesday, 07'th May 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL ) Q1 2024 Results Conference Call May 7, 2024 8:00 AM ET Company Participants Tina Ventura - Chief IRO Bill Sibold - CEO Mardi Dier - CFO Conference Call Particip
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
07:00am, Tuesday, 07'th May 2024
CONSHOHOCKEN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis
Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label
04:30pm, Tuesday, 30'th Apr 2024
MDGL has launched Rezdiffra, the first drug approved for nonalcoholic steatohepatitis (NASH). Rezdiffra faces competition from potential off-label use of GLP-1RA drugs like semaglutide and tirzepatide
Madrigal Statement on the Passing of Dr. Stephen Harrison
04:00pm, Wednesday, 24'th Apr 2024
CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison.
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 16'th Apr 2024
CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), tod
